Aripiprazole
Product Images NDC 50436-0897

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 50436-0897). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

C103b8f2-figure-01 (Aripiprazole Tablets 1)

Chemical structure of aripiprazole showing its molecular framework including two chlorine atoms, multiple rings, and various functional groups.*

FDA Label Image

Fig-1 (Aripiprazole Tablets 2)

A chart titled 'Effect of Other Drugs on Aripiprazole' showing a comparison of fold change and 90% confidence intervals for various drugs impacting aripiprazole pharmacokinetics. The x-axis shows change relative to reference (without interacting drug), ranging from 0.0 to 3.0. The y-axis lists drug classes and specific inhibitors, inducers, acid blockers, and other drugs, with separate markers for AUC and Cmax values for each drug interaction.*

FDA Label Image

Fig-2 (Aripiprazole Tablets 3)

A pharmacokinetic chart showing the effect of various drugs on Dehydro-Aripiprazole levels, indicated as fold change with 90% confidence intervals. The x-axis represents change relative to reference without interacting drugs, and the y-axis lists drugs including CYP3A4 and CYP2D6 inhibitors and inducers, gastric acid blockers, and others such as valproate, lithium, and lorazepam, with measured AUC and Cmax values.*

FDA Label Image

Fig-3 (Aripiprazole Tablets 4)

A forest plot chart titled 'Effect of Aripiprazole on Other Drugs' displaying fold change and 90% confidence intervals for various drugs metabolized by enzymes CYP2D6, CYP2C9, 2C19, and UGT1A4. The x-axis shows change relative to reference (without interacting drug) from 0.0 to 3.0, with data points for pharmacokinetic parameters including AUC and Cmax for drugs such as dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram.*

FDA Label Image

Fig-4 (Aripiprazole Tablets 5)

A forest plot chart titled 'Aripiprazole Fold Change and 90% CI' displaying pharmacokinetic (PK) changes in AUC and Cmax relative to reference values. The plot compares changes across special populations including CYP2D6 metabolizer status, gender, age groups, and hepatic and renal impairment levels, with fold changes represented on the x-axis ranging from 0.5 to 3.0.*

FDA Label Image

Fig-5 (Aripiprazole Tablets 6)

A pharmacokinetic (PK) forest plot showing dehydro-aripiprazole fold change with 90% confidence intervals (CI) across various subgroups: CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. The variables plotted are AUC and Cmax fold changes, with the x-axis indicating change relative to reference values.*

FDA Label Image

Fig-6 (Aripiprazole Tablets 7)

A Kaplan-Meier survival curve chart showing the proportion of subjects with relapse over days from randomization. The chart compares two groups: Aripiprazole (solid blue line) and Placebo (dashed red line). The x-axis represents days from randomization up to 182 days, and the y-axis represents the proportion with relapse, ranging from 0 to 1. A risk table below the graph shows the number of subjects at risk at different time points for each group.*

FDA Label Image

01 (Aripiprazole Tablets 8)

A line chart comparing the proportion of subjects with relapse over days from randomization for Aripiprazole versus placebo. The x-axis shows days from 0 to 182, and the y-axis shows the proportion with relapse from 0.0 to 1.0. The chart includes the number of subjects at risk for each group at various time points.*

FDA Label Image

0102 (Aripiprazole Tablets 9)

A Kaplan-Meier curve chart comparing the proportion with relapse over time between Aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The chart includes a table indicating the number of subjects at risk at various time points for both Aripiprazole and placebo groups.*

FDA Label Image

Label Image (Lbl504360897)

Aripiprazole Tablets, USP 5 mg, Unit Dose by Unit Dose Services. The packaging label indicates one tablet per unit dose pouch, each containing 5 mg of aripiprazole. It includes storage instructions, pharmacist information, manufacturer details (Amneal Pharmaceuticals Pvt. Ltd., India), and repackager details (Unit Dose Services, LLC, Dayton, OH).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.